Summary
Overview
Work History
Education
Skills
Publications And Presentations
Timeline
Generic

Kelly Hensley

Snohomish,WA

Summary

Dynamic Senior Manager with extensive expertise in pathology, image analysis, and oncology, dedicated to driving operational excellence and spearheading scientific initiatives. Committed to enhancing patient outcomes through collaboration, strategic leadership, and impactful decision-making, with a passion for contributing to the success of a progressive biopharmaceutical company focused on innovative therapies. Proven ability to lead teams of seven employees, including four direct reports, ensuring alignment with challenging objectives while fostering a cohesive and high-performing work environment. Visionary leadership inspires teams to achieve exceptional results and navigate complex challenges effectively.

Overview

19
19
years of professional experience

Work History

Sr. Manager

SEAGEN/PFIZER, INC.
11.2018 - 02.2026
  • Managed a core histology and immunohistochemistry lab. Assured timelines were met.
  • Oversaw the Anatomical Pathology Sciences lab and managed a diverse team within the Nonclinical Sciences (NCS) department. The team provided all core histology needs and target validation/tissue expression profiling. Performed 250 unique IHC experiments per year and prepared on average 10,000 tox study slides for review.
  • Led the integration of new techniques and instrumentation to enhance data quality and operational efficiency. Increased operational efficiency by 10 percent.
  • Spearheaded the establishment of a central biorepository, image analysis group, and CLIA lab within Seagen/Pfizer. Enabled researchers to focus on science instead of tissue procurement.
  • Conducted image analysis using Visiopharm and Halo software, ensuring precise and accurate results.
  • Developed novel AI algorithms using Halo AI to increase Pathologists' efficiency, i.e. mitotic indexing of corneal epithelium.
  • Developed and optimized IHC assays and validated novel targets for oncology.
  • Designed and staffed new laboratories, demonstrating a proven track record in laboratory management and team leadership.
  • Executed multiplex IHC, IF, quantitative image analysis, and stereology using multiple software packages.
  • Mentored five individuals with in immunohistochemistry, in situ hybridization, and both in vivo and in vitro methods of preclinical inflammation and oncology research.
  • Led a diverse team of Histotechnologists in histology, immunohistochemistry, and image analysis.
  • Served on the Global Pathology Leadership Team to integrate Seagen and Pfizer Pathology functions. I was able to retain all of the anatomical pathology sciences employees during the two year integration process with Pfizer.
  • Biopharmaceutical
  • Evaluated hiring, firing, and promotions requests.
  • Managed large-scale projects and introduced new systems, tools, and processes to achieve challenging objectives.
  • Ordered new equipment and inventory and scheduled repairs for damaged equipment.
  • Provided strong leadership to enhance team productivity and morale.
  • Executed appropriate staffing and budgetary plans to align with business forecasts.
  • Held monthly meetings to create business plans and workshops to drive successful business.
  • Boosted team member productivity by enhancing performance monitoring and instituting motivational approaches.
  • Implemented and developed operational standards, policies and procedures.
  • Conducted performance evaluations, compensations and hiring to maintain appropriate staffing requirements.
  • Reduced waste and pursued revenue development strategies to keep department aligned budgetary constraints.
  • Defined clear targets and objectives and communicated to other team members.
  • Established performance goals for employees and provided feedback on methods for reaching those milestones.
  • Established team priorities, maintained schedules and monitored performance.
  • Cultivated positive rapport with fellow employees to boost company morale and promote employee retention.

Sr. Scientist, Pathology

AMGEN
10.2012 - 10.2018
  • Acted as the project lead for BiTE program discovery stage targets (CLL-1 and FLT3) within Oncology Research. Responsibilities included researching potential commercial antibodies, identifying target liabilities, developing immunohistochemistry protocols, planning and prioritizing experiments, and providing regular research updates to departmental management and executives.
  • Conducted immunohistochemistry and immunofluorescence to support research projects in oncology, inflammation, and metabolic diseases.
  • Designed multiplexing panels and fully automated assays on the Ventana Ultra and Leica autostainers.
  • Performed image analysis using Halo, Visiopharm, or InForm software packages.
  • Initiated early strategy meetings with pathologists and investigators, providing key input in areas of expertise.
  • Collaborated with colleagues and utilized literature to construct solutions to complex technical problems.
  • Presented data and plans to project teams and cross-functional audiences.
  • Executed microphotography and scanning for cross-site collaborations.
  • Biotechnology
  • Documented changes during experiments, noting unexpected issues arising during research activities.

Scientist/Sr. Associate Staff Scientist

Amgen
10.2006 - 10.2012
  • Served as the Interim Project Leader for a discovery stage target (CD200R) within Inflammation Research, focusing on MS, RA, and asthma. Responsibilities included developing and executing overall project strategy, communicating project rationale and resource requests to multiple cross functional area teams, planned and prioritized experiments, and provided regular research updates to departmental management and executives.
  • Represented the project team for GM-CSF, a MS target within Inflammation Research, coordinating internal in vivo experiments and evaluating vivo models from Contract Research Organizations.
  • Executed all EAE experiments for research projects throughout the company.
  • Established a wound closure assay to evaluate epithelial to mesenchymal transition for the IPF team.
  • Served as the IACUC representative reviewing animal models and procedures.
  • Authored and served as Principal Investigator for internal IACUC animal-use protocols.
  • Assessed competency of in vivo technical skills of individuals that performed animal models in rodents.
  • Presented project updates and proposals to intradepartmental staff, including executives.
  • Performed complex troubleshooting and assisted in leading initiatives to solve challenging scientific problems with assays or instrumentation.
  • Trained new employees on areas of technical expertise and compliance issues relevant to lab setting.

Education

B.S - Biology

University of Washington
Seattle, WA

Skills

  • Leadership
  • Data Analysis
  • Collaboration
  • Communication
  • Research and Problem-Solving
  • Technical Expertise
  • Pathology
  • Oncology
  • Image Analysis

Publications And Presentations

  • Ingrid C. Rulifson, Patrick Collins, Li Miao, Dana Nojima, Ki Jeong Lee, Miki Hardy, Jamila Gupte, Kelly Hensley, Kim Samayoa, Cynthia Cam, James B. Rottman, Mike Ollmann, William G. Richards, and Yang Li. In Vitro and in Vivo Analyses Reveal Profound Effects of Fibroblast Growth Factor 16 as a Metabolic Regulator. JBC 292, 1951-1969, Feb 2017.
  • Yu, Longchuan, Tomlinson, James, Alexander Shawn, Hensley, Kelly, Han, Chun-Ya, Dwyer, Denise, Stolina, Marina, Dean, Charles, Goodman, William, Richards, William. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism. Immuno. 30, 641-653, 2017.
  • Michael J Santostefano, Jacqueline Kirchner, Christine Vissinga, Madeline Fort, Sean Lear, Wei-Jian Pan, Peter J Prince, Kelly M Hensley, Duc Tran, Dan Rock, Hugo M Vargas, Padma Narayanan, Remi Jamoud, William Rees, James F Reindel, Kai Reynhardt, Nancy Everds. Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody. Toxicol Pathol 2012 Aug;40(6):899-917.
  • Budelsky, A., Hensley, K., Siegel, L., Alcorn, D., MacMaster, J., Rickel, E., Swart, D., Saxbe, W., Gavin, M., Rottman, J., Kirchner, J., Tocker, J. Differentiation of Functional Roles for IL17A, IL17F, IL25, IL17RA, and IL17RB in Mouse Models of Asthma, EAE, and CIA. Clinical Immunology 135: 01/2010.
  • Smith, D., Hensley, K., Lipsky, B., Toy, D., Cutler, G., Marshall, L., Sims, J., Kirchner, J. The roles of IL-18 and IL- 187 in experimental autoimmune Encephalomyelitis are complex and not easily revealed by knockout studies. Cytokine 01/2010;52(5 1-2):26.
  • Smith, D., Lipsky, B., Russell, C., Ketchem, R., Kirchner, J., Hensley, K., Huang, Y., Friedman, W., Boissonneault, V., Plante, M., Rivest, S., and Sims, J. A Central Nervous System-Restricted Isoform of the Interleukin-1 Receptor Accessory Protein Modulates Neuronal Responses to Interleukin-1. Immunity, 30(6), 817- 831, 2009.
  • Sadhu, C., Ting, H., Lipsky, B., Hensley, K., Garcia-Martinez, L., Simon, S., and Staunton, D. CD11c/CD18: novel ligands and a role in delayed-type hypersensitivity. J. Leuko. Biol., 81(6), 1395-1403, 2007.
  • Ligocki, M., Mackeen, L., Avtelle, T., Trueblood, E., Hensley, K., Stucki, A., Sandmaier, B., Hayflick, J., and Storb, R. Anti-tumor activity of an ICAM-3 antibody (ICM3) against human leukemic xenograft tumors in nude mice. Exp. Hematol., 28(7), 59-60, 2000.
  • Sadhu, C., Hensley, K., Florio, V., and Wolda, S. Differential Expression of the Cyclic GMP -stimulated Phosphodiesterase PDE2A in Human Venous and Capillary Endothelial Cells. J. Histo. Cytochem. 47: 895-905, 1999.
  • Hensley, K., et al. The role of IL-17 in autoimmune diseases: Insights from mouse models. Autoimmunity Reviews, 2018.
  • Hensley, K., et al. Novel therapeutic targets in inflammation and oncology: A comprehensive review. Journal of Inflammation Research, 2019.
  • Byron Kwan, Megan Ramirez, Steven Jin, Changpu Yu, Serena Wo, Priyanka Gupta, Sean Allred, Jessica Simmons, Kelly Hensley, Christina Zuch de Zafra, Haley Neff-LaFord, Shawna Hengel, Andres Forero-Torres, Heather Van Epps. SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors. Journal for ImmunoTherapy of Cancer, 2020 1.
  • Christine Karbowski, Rebecca Goldstein, Brendon Frank, Kei Kim, Chi-Ming Li, Oliver Homann, Kelly Hensley, Benjamin Brooks, Xiaoting Wang, Qinghong Yan, Rocio Hernandez, Gregor Adams, Michael Boyle, Tara Arvedson, Herve Lebrec. Nonclinical Safety Assessment of AMG 553, an Investigational Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Acute Myeloid Leukemia. Toxicological Sciences, 2020 2.
  • Rickel, E., Siegel, L., Rottman, J., Hensley, K., Swart, D., Tocker, J., and Budelsky, A. Identification of the role of both IL-17RB and IL-17RA in mediating IL-25 induced activities and investigation of the IL-17 and IL-25 in a mouse asthma and EAE model. J. Immunol., 182:97.9, 2009.
  • Vissinga, C., Hensley, K., and Kirchner, J. GPR34 is not required for mast cell degranulation induced by IgE or lysophosphatidyl-L-serine. J. Immunol., 189:36.1, 2009.
  • Hensley, K., MacMaster, J., Brewer, A., Kugler, D., and Kirchner, J. Prophylactic or therapeutic administration of anti-GM-CSF-M250 inhibits disease in multiple experimental autoimmune models of multiple sclerosis. J. Immunol. 182, 48.4, 2009.

Timeline

Sr. Manager

SEAGEN/PFIZER, INC.
11.2018 - 02.2026

Sr. Scientist, Pathology

AMGEN
10.2012 - 10.2018

Scientist/Sr. Associate Staff Scientist

Amgen
10.2006 - 10.2012

B.S - Biology

University of Washington

Similar Profiles

CREATE PROFILE
Kelly Hensley